Pharmacokinetics of intravenous recombinant human granulocyte colony‐stimulating factor (rhG‐CSF) in children receiving myelosuppressive cancer chemotherapy: Clearance increases in relation to absolute neutrophil count with repeated dosing

• Published in: American journal of hematology Vol. 54; no. 2; pp. 124 - 130
• Main Authors: Sturgill, Marc G., Huhn, Richard D., Drachtman, Richard A., Ettinger, Alice G., Ettinger, Lawrence J.
• Format: Journal Article
• Language: English
• Published: New York Wiley Subscription Services, Inc., A Wiley Company 01.02.1997; Wiley-Liss
• Subjects: Adolescent; Antineoplastic Agents - therapeutic use; Biological and medical sciences; Bone Marrow - drug effects; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug toxicity and drugs side effects treatment; Enzyme-Linked Immunosorbent Assay; Female; Granulocyte Colony-Stimulating Factor - administration & dosage; Granulocyte Colony-Stimulating Factor - blood; Granulocyte Colony-Stimulating Factor - pharmacokinetics; Humans; Injections, Intravenous; Leukocyte Count; Male; Medical sciences; neutrophils; Neutrophils - pathology; pharmacokinetics; Pharmacology. Drug treatments; recombinant human granulocyte colony‐stimulating factor; Recombinant Proteins; Toxicity: blood; Antineoplastic agent; Ewing sarcoma; Intravenous administration; Toxicity; Diseases of the osteoarticular system; Granulocyte; Rhabdomyosarcoma; Hemopathy; Bone marrow aplasia; Clearance; Granulocyte colony stimulating factor; Lymphoproliferative syndrome; Complication; Acute lymphocytic leukemia; Child; Human; Sarcoma; Acute; Cytokine; Malignant hemopathy; Malignant tumor; Non Hodgkin lymphoma; Numeration; Striated muscle disease; Chemotherapy; Treatment; Polypeptide; Neutrophil; Bone; Pharmacokinetics
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/(SICI)1096-8652(199702)54:2<124::AID-AJH5>3.0.CO;2-Z

Limited evidence suggests increased efficacy of rhG‐CSF by subcutaneous (SQ) compared with intravenous (IV) administration. To examine the possibility that rapid elimination of IV rhG‐CSF could substantially shorten the duration of systemic exposure and could explain a difference in pharmacodynamics, we characterized the pharmacokinetic profile of IV rhG‐CSF for comparison to that previously reported for SQ administration. Twelve children were randomly assigned to receive 10 or more days of IV rhG‐CSF at dosages of 5 or 10 μg/kg a day beginning 24 hr after chemotherapy. Enzyme‐linked immunosorbent assay (ELISA) was used to measure rhG‐CSF concentrations in timed serum samples on days 1 and 10. Pharmacokinetic parameters were estimated by nonlinear, least squares regression. All serum concentration‐time profiles were best described by a two‐compartment model of elimination. Mean t1/2β values ranged from 3.68 ± 0.86 to 22.4 ± 12.0 hr. ANC was correlated with log CLT (r = 0.72, P < 0.05), and inversely with log dose‐adjusted AUC (r = −0.75, P < 0.05) and log dose‐adjusted Cmax (r = −0.65, P < 0.05). Estimated duration of serum rhG‐CSF concentrations above 1 ng/ml exceeded 24 hr for all but the 5 μg/kg cohort on day 1. Pharmacokinetic parameters of IV rhG‐CSF are similar to those previously reported for SQ administration in children treated with myelosuppressive cancer chemotherapy. Daily IV administration should be suitable alternative route of administration in this patient population. Am. J. Hematol. 54:124–130, 1997 © 1997 Wiley‐Liss, Inc.